Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 10
2008 27
2009 17
2010 11
2011 12
2012 9
2013 3
2014 5
2015 3
2016 8
2017 5
2018 4
2019 2
2020 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Spinler SA. Spinler SA. Am J Manag Care. 2009 Mar;15(2 Suppl):S42-7. Am J Manag Care. 2009. PMID: 19355808 Free article. Review.
Percutaneous coronary intervention (PCI) with stenting is increasingly being utilized for acute coronary syndromes (ACS), and the debate over the safety and efficacy of drug-eluting stents (DESs) versus bare-metal stents (BM …
Percutaneous coronary intervention (PCI) with stenting is increasingly being utilized for acute coronary syndrom …
Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment.
Byrne RA, Sarafoff N, Kastrati A, Schömig A. Byrne RA, et al. Drug Saf. 2009;32(9):749-70. doi: 10.2165/11316500-000000000-00000. Drug Saf. 2009. PMID: 19670915 Review.
Drug-eluting stent (DES) therapy has represented a very significant milestone in the evolution of percutaneous coronary intervention (PCI) therapy. ...The principal safety parameters are overall mortality, myocardial infarction (MI) and …
Drug-eluting stent (DES) therapy has represented a very significant milestone in the evolution of percutaneous …
On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes.
Poorhosseini H, Kassaian SE, Aghajani H, Alidoosti M, Hajizeinali AM, Salarifar M, Nematipour E, Amirzadegan AR, Sheikhfathollahi M, Shafiee N, Hakki-Kazazi E, Tokaldany ML. Poorhosseini H, et al. Tex Heart Inst J. 2012;39(1):24-9. Tex Heart Inst J. 2012. PMID: 22412223 Free PMC article.
In this retrospective study, we compared the in-hospital and long-term outcomes of the on-label and off-label uses of drug-eluting stents.From April 2003 through June 2007, 1,538 patients underwent percutaneous coronary i …
In this retrospective study, we compared the in-hospital and long-term outcomes of the on-label and off-label uses of …
Drug-eluting stents in primary percutaneous coronary intervention for ST-elevation myocardial infarction: an up-to-date review of the literature.
Ehdaie A, Lee MS. Ehdaie A, et al. Minerva Cardioangiol. 2009 Oct;57(5):645-55. Minerva Cardioangiol. 2009. PMID: 19838154 Review.
Drug-eluting stents (DES) have been approved by the Food and Drug Administration for percutaneous coronary intervention (PCI) in the treatment of stable coronary disease but not in the treatment of acute myocardial infarctio …
Drug-eluting stents (DES) have been approved by the Food and Drug Administration for percutaneous coro …
Off-label use of stents: bare-metal versus drug-eluting stents.
Girod JP, Mulukutla SR, Marroquin OC. Girod JP, et al. Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1095-106. doi: 10.1586/14779072.6.8.1095. Expert Rev Cardiovasc Ther. 2008. PMID: 18793112 Review.
Drug-eluting stents (DES) became the default strategy for percutaneous revascularization due to their improved intermediate-term outcomes when compared with bare-metal stents (BMS) in the pivotal randomized, controlled trials. ...There is an ove …
Drug-eluting stents (DES) became the default strategy for percutaneous revascularization due to their improved i …
Atheroma and coronary bifurcations: before and after stenting.
Yazdani SK, Nakano M, Otsuka F, Kolodgie FD, Virmani R. Yazdani SK, et al. EuroIntervention. 2010 Dec;6 Suppl J:J24-30. doi: 10.4244/EIJV6SUPJA5. EuroIntervention. 2010. PMID: 21930487 Review.
First generation drug-eluting stents (DES) have significantly improved the treatment options for patients with symptomatic coronary artery disease by decreasing rates of restenosis after percutaneous coronary revascularisation procedures. …
First generation drug-eluting stents (DES) have significantly improved the treatment options for patients with symptoma …
Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use.
Park KH, Kim U, Lee CH, Son JW, Park JS, Shin DG, Kim YJ, Cho JH. Park KH, et al. Korean J Intern Med. 2016 Jul;31(4):678-84. doi: 10.3904/kjim.2015.045. Epub 2016 Mar 25. Korean J Intern Med. 2016. PMID: 27017384 Free PMC article.
BACKGROUND/AIMS: To compare the clinical outcomes of 'on-label' and 'off-label' drug-eluting stents (DESs) over a 5-year follow-up period. METHODS: A total of 929 patients that underwent percutaneous coronary intervention …
BACKGROUND/AIMS: To compare the clinical outcomes of 'on-label' and 'off-label' drug-eluting stents …
Stable angina: management.
[No authors listed] [No authors listed] London: National Institute for Health and Care Excellence (NICE); 2016 Aug. London: National Institute for Health and Care Excellence (NICE); 2016 Aug. PMID: 32207889 Free Books & Documents. Review.
Statins and other secondary prevention treatments were not used when the trials were carried out and these treatments have a significant effect on morbidity and mortality. Percutaneous revascularisation techniques have developed, from balloon angioplasty to bare metal s …
Statins and other secondary prevention treatments were not used when the trials were carried out and these treatments have a significant eff …
107 results